The identified variants included mono-allelic mutations in NFKB1, STAT3, CTLA4, PIK3CD, and IKZF1, and bi-allelic mutations in LRBA and STXBP2 (38), and the authors concluded that WES combined with analysis of PID-associated genes is a cost-effective way to identify variants with potential benefits for risk stratification and targeted treatment for certain subgroups of CVID patients. This evidence concerns the gene CTLA4 and common variable immunodeficiency.